Phase 1 Trial of Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma

This study is testing a new combination of two drugs to see if they can help treat aggressive brain tumors that have returned after initial treatment. It is a 'Phase 1' trial, which means the primary goal is to determine the safest dose and monitor how the body reacts to this new approach.

This trial is for adults (and some teenagers) who have been diagnosed with a specific type of high-grade glioma that has returned after standard treatments like radiation. You must be in generally good health, free of certain autoimmune conditions, and able to commit to the study's requirements.

Participants will receive two medications, nivolumab and azacitidine, delivered directly into the spinal fluid. You will also have regular check-ups, including imaging scans that use special dyes to help doctors see how the tumor is responding to the treatment.

The study is currently enrolling patients by invitation at a medical center in Iowa City, Iowa. Because it is by invitation only, please speak with your oncology team to see if you are a candidate for this specific study.